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Abstract
Background Multiple endocrine neoplasia type 2 (MEN 2)
is caused by a RET mutation in chromosome 10. All MEN 2
patients develop medullary thyroid carcinoma (MTC). The
age-related risk of MTC is associated with the type of RET
mutation. Our aim was to identify prognostic factors asso-
ciated with recurrent MTC in MEN 2 patients.
Methods In a nationwide case–control study, all patients
who underwent total thyroidectomy in the Netherlands
under the age of 20 years were classified into standard (1),
high (2), or very high risk (3) for MTC based on RET-
mutation type. Disease-free patients were compared with
those with recurrent disease.
Results A total of 93 patients were included in the study.
Sixty-six percent had MTC on histology, the youngest
being 1 year old. Codon 634 was most affected. Sixteen
(18%) patients had persistent or recurrent disease, one of
whom died. Significantly associated determinants of out-
come in univariate analysis were higher age at surgery, no
age-appropriate prophylactic surgery according to risk
level, elevated preoperative calcitonin levels, affected
codon, and the presence of lymph node metastases at sur-
gery. On multivariate analysis only age of surgery was
the single independent factor associated with persistent
disease.
Conclusions Prophylactic thyroidectomy beyond the
recommended age is associated with persistent/recurrent
disease. In addition, codon 634 mutation is associated with
a high risk of recurrence requiring early surgery for all
these patients.
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Introduction
Multiple endocrine neoplasia type 2 (MEN 2) syndrome is
a rare autosomal inherited complex of endocrine tumors
caused by a mutation in the REarranged during Transfec-
tion (RET) proto-oncogene located on chromosome 10.
According to the mutation type, MEN 2 can be divided into
MEN type 2A and 2B. Almost all MEN 2A and 2B patients
develop medullary thyroid carcinoma (MTC). MTC is a
neuroendocrine cancer of the calcitonin-producing para-
follicular C cells. In MEN 2A, pheochromocytomas and
primary hyperparathyroidism can also present in, respec-
tively, 40 and 20-30% [1, 2]. In MEN 2B, primary
hyperparathyroidism is absent; however, this disease is also
characterized by the development of mucosal neuromas,
intestinal ganglioneuromas, and, in some instances, a
Marfanoid habitus. Familial medullary thyroid carcinoma
(FMTC) is an inherited disorder caused by RET leading
only to MTC. The progression from C-cell hyperplasia, the
precursor lesion of MTC, to intrathyroidal MTC and
eventually lymphatic and distant metastatic spread is age
related [3–5].
In 1993 and 1994, the relationship between germline RET
proto-oncogene mutations and MEN type 2A and type 2B
syndrome became apparent [6–8]. Since then, DNA analysis
has become available to identify patients with hereditary
MTC and to perform predictive testing in asymptomatic
family members of mutation carriers. A genotype-pheno-
type relationship exists for different RET proto-oncogene
mutations [9, 10]. The expression of MTC in terms of
aggressiveness varies between the different codon muta-
tions. Based on this genotype-phenotype relationship,
patients are classified into different risk levels [11].
In earlier years, patients underwent surgery when they
presented with a clinically apparent thyroid nodule or had
elevated plasma calcitonin levels. By then, many had
already progressed into late-stage MTC with lymph node
or distant metastases. The availability of presymptomatic
DNA analysis by direct detection of germline RET proto-
oncogene mutations provided a rationale to perform pro-
phylactic surgery because in 95% of patients with MEN 2
and FMTC, C-cell hyperplasia develops into MTC [4, 9,
10, 12, 13].
In recent years, timing of prophylactic thyroidectomy in
asymptomatic carriers of germline RET gene mutations has
been customized based on the age and type of mutation [9,
10]. In an effort to further optimize the management of
these children, we conducted a nationwide study, including
all Dutch patients who underwent total thyroidectomy in
childhood in the past 25 years. We set out to study the
differences in treatment for patients operated on at the age
recommended by the current guidelines and those operated
on at an older age. The second purpose of this study was to
assess any differences in treatment and outcome in patients
treated in the era before and after genetic testing became
available. Finally, our aim was to analyze prognostic risk
factors for recurrent MTC in these patients.
Materials and methods
This case control study was performed in the cohort of all
Dutch patients with a germline RET mutation who were
operated on in one of the eight university hospitals in the
Netherlands from 1980 up until 2006. Inclusion criteria
were MEN 2 syndrome, 19 years or younger at the time of
surgery, and had undergone a total thyroidectomy.
The participating centers were the Free University
Medical Center Amsterdam (n = 4), Leiden University
Medical Center (n = 5), Academic Hospital Maastricht
(n = 8), Radboud University Medical Center Nijmegen
(n = 8), Academic Medical Center Amsterdam (n = 9),
Erasmus Medical Center Rotterdam (n = 12), University
Medical Center Groningen (n = 19), and University
Medical Center Utrecht (n = 28).
In total, 93 patients were identified and data were col-
lected retrospectively from hospital records in the partici-
pating centers by two authors (JMJS and MRV). Patients
were divided into those who were operated on up to 1994
when predictive genetic testing became available (‘‘pre-
RET era’’) and those after 1994 (‘‘RET era’’). The follow-
up of the patients included in this study was part of regular
medical care.
The approaches described in this article did not involve
any randomization, experimental intervention, or ques-
tionnaire, and the anonymity of patients was not breached.
Therefore, this article meets the conditions required
under Dutch law (WGBO) for making medical and/or
personal data available for statistical or other scientific
research.
Surgery
Almost all 93 patients were operated on by a team con-
sisting of a pediatric surgeon and an endocrine surgeon. All
patients underwent total thyroidectomy. An additional
prophylactic lymph node dissection of the central zone of
the neck was not performed routinely. A central or lateral
neck dissection was performed in case a suspicious lymph
node was present during the surgery or on preoperative
imaging. In the ‘‘pre-RET’’ era (until 1994), patients were
operated on based on family history and/or elevated basal
and/or stimulated calcitonin levels. In the ‘‘RET era’’ (after
1994), most patients were operated on based on the
mutation analysis. Whenever possible, the parathyroid
glands were left in situ.
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Laboratory tests
Calcitonin and pentagastrin-stimulated calcitonin levels
were measured to determine the level of tumor activity. We
could not retrieve all calcitonin levels, especially from the
pre-RET era. However, it was often noted whether calci-
tonin levels were elevated. Furthermore, as each center
used its own test methodology with according reference
values (which differed between the participating hospitals
and changed during the study period), we indicated whe-
ther these levels were elevated according to the local ref-
erence values [14]. Patients were considered cured when
postoperative (pentagastrin-stimulated) calcitonin was in
the lower limits of the reference values.
Genetic testing
In the Netherlands, screening for mutations in a RET
proto-oncogene is carried out in one central genetics
laboratory at the University Medical Center Utrecht.
Mutation analysis was performed by PCR amplification
followed by direct sequence analysis of exons 10, 11, 14,
13, 15, and 16 of the RET proto-oncogene. Sporadic cases
of MTC were identified by mutation analysis of RET
exons 15 and 16 in DNA isolated from tumor samples,
following a normal RET mutation screening result on
DNA from peripheral blood. All results of RET mutation
screening were confirmed on a duplicate DNA sample.
(PCR conditions and oligonucleotide primer sequences
are available upon request from RBL.) Based on the
affected codon, patients were stratified into three levels of
risk of developing MTC according to the 2001 guidelines
[11]: standard risk (level 1; codons 768, 790, 791, 804,
and 891), high risk (level 2; codons 630, 634, 609, 611,
618, and 620), and very high risk (level 3; codons 918,
883, and 922) (Table 1) [15].
Pathological examination and tumor staging
Pathological examination of the thyroid specimens was
performed separately at each hospital. In general, the thy-
roid specimen was fixed and transversally laminated in thin
sections, which were then prepared for light microscopy.
The transition zone between the upper and the middle third
of the thyroid lobes was the focus of attention, as C cells
are normally situated in this area. The sections were
investigated for the presence of C cells; characterization of
cytoplasmic levels of calcitonin, chromogranin, and car-
cinoembryonic antigen (CEA); destructions of follicles;
and amyloidal formation and invasion of vessels and or
nerves by these cells. C-cell hyperplasia was diagnosed
when more than 7 C cells per follicle were present, there
were clusters of C cells, or more than 20 C cells were
observed per field. MTC was diagnosed in case of atypia of
C cells and their nuclei in combination with follicular basal
membrane destruction as a sign of infiltrative C-cell pro-
liferation [5].
Statistical analysis
Statistical analysis was performed using SPSS 16 (SPSS
Inc., Chicago, IL). In this case control study, children
with persistent or recurrent MTC were identified. Their
exposure to possible prognostic factors was compared
with those who were cured. Patients with C-cell hyper-
plasia were excluded from the analysis. Associations
between categorical variables were evaluated with uni-
variate analysis by v2 analysis, and the in case of a
sample size of 5 or fewer, by the Fischer’ s exact test.
Student’s t test was used to analyze differences in mean
values, the Mann–Whitney U test was used for differences
in median values, and the ANOVA test was used for
comparison of multiple groups. The correlation between
factors was studied. A binary logistic regression analysis
was performed to determine factors associated with
recurrent disease. A p value of less than 0.05 was con-
sidered to be significant. Factors included in the multi-
variate analysis were age at surgery, the affected codon,
the risk level 1, 2, or 3, presence of lymph node metas-
tasis, and preoperative calcitonin levels. Furthermore, for
each patient it was determined whether surgery had been
performed at an appropriate age as recommended by the
guidelines (age-appropriate prophylactic surgery) and if
the surgery had been performed in the pre-RET era
(before 1994) or in the RET era (after 1994) [11]. This
factor was included in the analysis as well.
Table 1 Risk level for MTC based on codon mutation
Risk level Codon Recommended age of surgery
1 Standard risk 768, 790, 791, 804, and 891 5–10 years
2 High risk 630, 634, 609, 611, 618, and 620 \5 years
3 Very high risk 918, 883, and 922 \6 months
Risk level of MTC based on the 1999 consensus statement from the Seventh International Workshop on Multiple Endocrine Neoplasia [11, 15]
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Results
Of the 93 patients identified, 38 (41%) were male and 55
(59%) female. Demographic, surgical, and follow-up data
are summarized in Table 2.
The majority of cases had MEN 2A syndrome (n = 87,
94%). The remaining patients had MEN 2B syndrome
(n = 6, 6%). Mutation analysis revealed that codon 634
(62 patients) was most frequently affected, followed by
codon 618 (10 patients), codon 611 (9 patients), codon 918
(6 patients), codon 620 (3 patients), and codon 804
(1 patient). In two patients, who underwent surgery in the
early 1980s, the genetic mutation could not be retrieved
from the national database. In Table 2, patient character-
istics are also given for patients operated on in the pre-RET
era and in the RET era.
The median age of all patients at surgery was 8.9 years
(IQR = 5.7–12.25). Patients who were operated on in the
pre-RET era were older than patients operated in the RET
era (10.6 vs. 7.8 years). A preoperatively elevated calci-
tonin level was found in 43 patients (46%). A central
compartment neck dissection was performed in 26
patients (28%) and a modified lateral neck dissection in 8
(9%), in most cases because of evident intraoperative
lymph node metastases (Table 2). Seven patients (7%)
developed definitive hypoparathyroidism (15% of patients
in the pre-RET era and 4% in RET era) and two (2%)
patients suffered from permanent laryngeal nerve damage
(none in the RET era). No association between the age at
surgery, a central neck dissection, or the complication rate
was found. None of the patients operated on who were
younger than 5 years (n = 14) developed a complication.
Five patients were not operated on prophylactically
because four already had a clinically apparent tumor and
another a palpable lymph node at the time of surgical
intervention.
Univariate analysis showed that a higher age at surgery,
no age-appropriate prophylactic surgery, affected codon
and risk level, preoperative calcitonin level, and lymph
node metastasis at operation were associated significantly
with persistent or recurrent disease (Table 3). No associa-
tion was seen with gender and different variants of codon
634 mutations. In multivariate analysis, only surgery at an
older age was significantly associated with persistent or
recurrent disease. In both the pre-RET era and the RET era,
the majority of patients were not operated on at an age-
appropriate age, but the percentage was significantly higher
in the pre-RET era (96 vs. 69%, p = 0.004).
On histological examination 61 patients had already
developed MTC (66%), whereas 30 (32%) patients dis-
played C-cell hyperplasia. Histological examination
showed no abnormalities in only two patients. One of these
patients had a Cys634Gly mutation and was operated on at
the age of 1 year. The other had a Cys620Ser mutation and
was 5 years of age at the time of surgery. There was no
significant difference in median age between patients with
C-cell hyperplasia and MTC (8.0 vs. 9.7 years). Lymph
node metastases were observed in eight patients and were
found only in patients with the Met918Thr mutation
associated with MEN 2B syndrome and the Cys634Arg
mutation, which is associated with MEN 2A syndrome.
The youngest patient with lymph node metastases was
7 years old and had a Cys634Arg mutation. The median
age at surgery of patients with histological lymph node
metastases was 13 years (IQR = 10-14). We found more
lymph node metastases in patients operated on in the pre-
RET era than in the RET era (Table 2). None of the patients
who had lymph node metastases had a normal preoperative
calcitonin level and none had calcitonin levels lower than
40 pg/ml. An overview of the earliest age at which MTC
was demonstrated per codon in our series compared to
literature is given in Table 4.
Follow-up
The median follow-up period was 7 years (IQR = 3–11).
At the time of the last visit, 75 (81%) patients were disease-
free according to the postoperative calcitonin levels. The
duration of follow-up was significantly different between
patients who had persistent or recurrent disease and those
who were cured. Thirteen of the 16 patients with persistent
or recurrent disease at follow-up had elevated basal calci-
tonin or pentagastrin-stimulated calcitonin levels preoper-
atively. None of these 16 patients had been operated on at
an appropriate age recommended by the guidelines. Three
of the 27 patients who had MTC and normal preoperative
calcitonin levels developed persistent or recurrent disease
(Table 3). All patients with lymph node metastases at
operation developed persistent or recurrent disease. All
eight patients underwent a central neck dissection and five
of them a lateral neck dissection as well. One MEN 2B
patient died at the age of 18 (i.e., 6 years postoperatively)
because of metastatic disease. No differences in presenta-
tion could be found between the different codon 634
mutations in terms of age at surgery and recurrent disease.
If we excluded patients who were operated on in the pre-
RET era, patients who had persistent or recurrent disease
were still older than those who were cured (12.3 vs.
7.9 years, p = 0.01) and were less frequently operated on
at an appropriate age (p = 0.034). These patients more
often had an elevated preoperative calcitonin level
(p = 0.04) and lymph node metastasis (p = 0.001) com-
pared to those who were cured. The duration of follow-up,
however, was not statistically different for both groups
after excluding patients from the pre-RET era (8.2 vs.
6.2 years).
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Table 2 Patient characteristics
Overall Pre-RET era (n = 25) (27%) RET era (n = 68) (73%) p valuea
Male:Female [n (%)] 38 (41%):55 (59%)
Median age (years) (IQR) 8.9 (5.7–12.6) 10.6 years (7.4–13.2) 7.8 (5.3–12.2) 0.022
Median follow-up (years) (IQR) 7 (3–11)
Codon [n (%)]
634 62 (67%)
Cys ? Arg 37
Cys ? Gly 9
Cys ? Tyr 8
Cys ? Trp 8
620 3 (3%)
Cys ? Arg 3
611 9 (10%)
Cys ? Tyr 9
618 10 (11%)
Cys ? Ser 8
Cys ? Tyr 1
Cys ? Arg 1
918 6 (6%)
Met ? Thr 6
804 Val ? Leu 1 (1%)
Unknown 2 (2%)
Risk level (n)
1 (standard risk) 1
2 (high risk) 84
3 (very high risk) 6
Unknown 2
Preoperative calcitonin levelsb ns
Normal 47 (51%) 14c 33
Elevated 43 (46%) 10 33
Unknown 3 (3%)
Age-appropriate surgery 0.004
Yes 22 (24%) 1 21
No 71 (76%) 24 47
Histology
C-cell hyperplasia 30 (32%) 7 22 ns
Medullary thyroid carcinoma 61 (66%) 18 43
Normal histology 2 (2%) 2
Lymph node metastasis 8 (9%) 5 3 0.02
Disease status at follow-up
Disease free 75 (81%)
Recurrent disease 16 (17%)
Disease-related death 1
Unknown 2
ns not significant
a Comparison for pre-RET era and RET era
b The mean age of patients with normal calcitonin levels was 8.8 years versus a mean age of 9.0 years for patients with elevated calcitonin levels
(not significantly different)
c Eleven of the 14 patients with normal calcitonin levels in the pre-RET era were operated on in the transition period between 1993 and 1994.
Genetic testing had become available in the UMCU at that time. Two of the other three patients had C-cell hyperplasia
856 World J Surg (2010) 34:852–860
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Discussion
Due to the well-organized infrastructure of the relatively
small country of the Netherlands, we were able to establish
a unique nationwide overview of all Dutch patients with
hereditary MTC who underwent a total thyroidectomy
based on their RET proto-oncogene mutation since 1980. In
the Netherlands all patients with MTC, especially young
patients, are operated on in a university hospital. We
included in our study all patients who underwent surgery in
those hospitals and it is therefore unlikely that our results
are biased because of selection of the population.
We evaluated potential prognostic factors responsible
for the outcome of prophylactic thyroidectomy in MEN 2
patients. The presence of lymph node metastasis, elevated
preoperative calcitonin levels, codon/risk level, no age-
appropriate prophylactic surgery, and a higher age at
surgery were associated with persistent/recurrent disease in
univariate analysis. Higher age at surgery was the only
independent prognostic variable for persistent or recurrent
disease in multivariate analysis. This could be an indication
that having the operation at an earlier age might lead to a
better outcome, thus preventing recurrent disease. It
appears that progression from C-cell hyperplasia into MTC
is age-related [4, 5, 9]. Twenty-three percent of the patients
who were operated on at a higher age than is currently
recommended by the guidelines developed recurrent dis-
ease. These data, once again underline the importance of
early, prophylactic surgery. However, the majority of
patients who had C-cell hyperplasia were not operated on
at the recommended age either. Based on the latter obser-
vation the argument could also be reversed because many
patients are cured despite the fact that they are operated on
at an older age than is recommended. We do, however,
Table 3 Factors associated with residual or recurrent disease in patients with MTC; univariate analysis
Factor Residual/recurrent disease
(n = 16, 27%) (n, %)
No evidence of residual/recurrent
disease (n = 44, 73%) (n, %)
Likelihood-ratio, p value
Preoperative calcitonin levels
elevated
N = 13 (81%) N = 20 (46%) 6.5, p = 0.011
Codona 634, n = 11 634, n = 35 10.7, p = 0.03
918, n = 4 618, n = 3
Unknown, n = 1 620, n = 1
611, n = 3
918, n = 1
Unknown, n = 1
Risk levelb 7.1, p = 0.007
1 n = 0 n = 0
2 n = 11 n = 42
3 n = 4 n = 1
Unknown n = 1 n = 1
Lymph node metastases at total
thyroidectomy, total n = 8
Lymph nodes present, n = 8 No lymph node metastases, n = 44 26.0, p \ 0.0001
Surgery at an appropriate age
based on risk level
No, n = 16 No, n = 31 9.3, p = 0.002
Yes, n = 0 Yes, n = 13
Surgery in the pre-RET era or
in the RET era
Pre-RET, n = 7 Pre-RET, n = 11 No significant difference
RET era, n = 9 RET era, n = 33 p = 0.14
t test or Mann–Whitney U test,
p value, and odds ratio
Mean age at surgeryc (years) (range) 12.1 (range = 1–19) 8.6 (range = 1–19) p = 0.002, 95% CI = 1.2–5.7
Mean follow-up (years) (±SD)d 12.3 (±7.1) 7.4 (±4.7) p = 0.004, 95% CI = 1.6–8.0
CI confidence interval
a We calculated the percentage of patients who had MTC who were cured per codon. Seventy-six percent of patients with codon 634, 100% of
patients with a 618, 620, and 611 mutation, and only 20% of those with a 918 mutation were cured
b When we analyzed this for risk level, 79% of the patients with risk level 2 and 20% with risk level 3 were cured
c Single factor also significantly associated in multivariate analysis
d The duration of follow-up, however, was not statistically different between both groups after excluding patients from the pre-RET era
(8.2 vs. 6.2 years)
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want to keep in mind that almost one-fourth of the patients
with MTC operated on at an older age developed persistent
or recurrent disease.
In our series, all patients with nodal metastases had
persistent or recurrent disease. Lymph node metastases
appeared only in patients who were operated on at a rela-
tively high age. One patient with persistent disease
(elevated calcitonin levels) was only 1 year old (codon
918 mutation). Therefore, we believe that prophylactic
thyroidectomy should not be delayed until after the age
recommended in literature.
Three risk levels have been identified in the literature.
Patients in the highest-risk level (level 3: codons 918, 883,
and 922) tend to have an aggressive presentation of MTC.
In our cohort, as expected, these patients presented with
MTC at an early age. Therefore, they are in need of a more
aggressive approach [9, 15].
Persistent and recurrent disease occurred only in chil-
dren with mutations in codons 918 and 634. Furthermore,
we found MTC in a 1-year-old child with a codon 634
mutation. Since no differences in biological behavior in
follow-up were observed between the different codon 634
mutations in our series, we feel that all patients with a
codon 634 mutation should be managed in the same
manner.
Having surgery at a younger age is believed to be
associated with a higher complication rate but we found no
evidence of this in our study. The complication rate is more
or less comparable with other series, even in the very
young [16]. In addition, in our study, performing a central
neck dissection was not associated with a higher compli-
cation rate. More complications occurred in the pre-RET
era group. Although the numbers are too small to draw any
firm conclusions, we think this difference between the
complication rates of the pre-RET era and the RET era may
was a result of the improvements in operative technique.
Since endocrine surgeons are more experienced in thyroid
surgery than pediatric surgeons, it is common practice in
the Netherlands to perform surgery together to decrease the
complication risk.
The youngest patient in our series with lymph node
metastasis was 7 years old and carried a codon 634
mutation. Another report describes a 5-year-old patient
with a nodal metastasis [17]. This is in contrast with two
other large series in which lymph node metastases in
patients younger than 11 and 14 years were not observed
[9, 10]. A central neck dissection is controversial. We do
not think it is necessary to perform a routine prophylactic
central neck dissection on patients younger than 5 years or
if preoperative calcitonin levels are normal in patients who
do not have MEN 2B syndrome. None of our patients with
lymph node metastases had a normal preoperative elevated
calcitonin. Machens [4] has suggested that a central neck
dissection be performed if preoperative calcitonin levels
are elevated, regardless of age.
As mentioned above, one MEN 2B (codon 918 muta-
tion) patient with MTC and persistent disease after surgery
was only 1 year old. In previous reports, MTC was
reported in a patient with this mutation within the first
6 months of life. Furthermore, persistent disease has been
reported within the first year of life [18–20]. Therefore, the
consensus guidelines [11] recommend a total thyroidec-
tomy together with a central lymph node dissection before
the age of 6 months in MEN 2B patients. Lymph node
metastases have been found in a 2.7-year-old child [18].
The 1 year old (codon 918) who had persistent disease in
our series did not undergo a central neck dissection. The
one patient who died in our series had MEN 2B syndrome
(Met918Tyr mutation) and had been operated on when
12 years old.
Children with a risk level 2 (codon 634, 611, 618, or 620
mutation) have a high risk of developing MTC. Some
reports have suggested that patients with a 634 mutation
may be regarded as a separate group with a higher risk of
MTC [9, 15]. When we regarded codon 634 as a separate
group, no recurrences of MTC were found in risk group 2
Table 4 Earliest presentation of medullary thyroid carcinoma in patients with a RET proto-oncogene mutation
Codon with RET
mutation and risk level
Earliest age at presentation of MTC (years) Earliest age of LN
metastases in current
series (years)
Earliest age at presentation
of MTC with LN metastases
(years) (Ref.)Current series (Ref.)
918 RL 3 1.13 0.75 [9] 11 2.7 [15]
634 RL 2 1.25 1.1 [15] 7 5 [15]
611 RL 2 6 3 [9] – 28 [21]
620 RL 2 6 5 [10] – 22 [15]
618 RL 2 12 7 [9] – 11 [10, 22, 23]
804 RL 1 – 6 [24] – 6 [24]
MTC medullary thyroid carcinoma, LN lymph node metastasis; -, not observed, RL risk level of MTC based on the 1999 consensus statement
from the Seventh International Workshop on Multiple Endocrine Neoplasia [11, 15]
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(codons 611, 618, and 620). However, the knowledge that
elevated preoperative calcitonin levels and/or suspicion of
lymph node involvement means an increased risk of
recurrent disease supports the advice of the consensus
meeting to perform surgery on patients younger than the
age of 5 [11].
It is generally believed that children with a relatively
low risk (risk level 1) of developing MTC because of a
germline mutation at codon 609, 768, 790, 791, 804, or 891
should undergo a total thyroidectomy as well. The bio-
logical behavior of MTC in this group is less aggressive,
which is confirmed in our cohort. The only patient in this
group did not have MTC. Controversy remains regarding
the age at which surgery should be performed. While some
believe that patients in this category should be operated on
before the age of 5, others advocate surgery in this risk
group before the age of 10 [11]. However, patient numbers
in our series were too small to draw any conclusions.
Limitations of this study are its retrospective nature and
its associated disadvantages such as missing data from
laboratory studies, the RET mutation in two cases, and
indications for central neck dissection. Furthermore, as
expected we found that patients operated on in the pre-RET
era were older than those in the RET era. A larger pro-
portion of the patients from the pre-RET era were not
operated on at an appropriate age and had more lymph
node metastases. However, when we excluded patients
from the pre-RET era, the same factors were still associated
with persistent disease.
Prophylactic thyroidectomy at a younger age is associ-
ated with less recurrence or metastasized MTC in patients
harboring a RET mutation. Recurrent disease was observed
only in patients with the 634 and 918 codon mutations who
did not undergo total thyroidectomy at an appropriate age.
Therefore, it seems justifiable to operate on patients in the
very-high-risk group at an early age, as is currently rec-
ommended. All patients with codon 634 mutations should
be treated equally.
Acknowledgments This work was supported by the Dutch Cancer
Society and the Michael van Vloten Fund of the Dutch Surgical
Association. On behalf of the endocrine and pediatric surgery work-
ing groups, we acknowledge and thank the following persons and
participating centers for their involvement in this nationwide study:
D. C. Aronson: Emma Children’s Hospital AMC, Academic Medical
Center/Free University Medical Center, Amsterdam; J. Th. M.
Plukker, Th. Links, A. H. Brouwers, R. Rassouli, T. Wiggers,
R. Hofstra, and J. W. de Groot: University Medical Center Groningen;
J. F. Hamming, B. A. Bonsing, and J. Kievit: Leiden University
Medical Center; N. D. Bouvy: Academic Hospital Maastricht; M.
Wijnen: Radboud University Medical Center Nijmegen; T. L. v.d.
Hoonaard and N. M. A. Bax: Erasmus Medical Center Rotterdam; J.
M. J. Schreinemakers, M. R. Vriens, I. H.M. Borel Rinkes, G. D.
Valk, R. B. van der Luijt, J. K. Ploos van Amstel, and D. C. v.d. Zee:
University Medical Center Utrecht.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Kraimps JL, Duh QY, Demeure M et al (1992) Hyperparathy-
roidism in multiple endocrine neoplasia syndrome. Surgery
112(6):1080–1086 (discussion 1086–1088)
2. Raue F, Frank-Raue K, Grauer A (1994) Multiple endocrine
neoplasia type 2 Clinical features and screening. Endocrinol
Metab Clin North Am 23(1):137–156
3. Machens A, Holzhausen HJ, Thanh PN et al (2003) Malignant
progression from C-cell hyperplasia to medullary thyroid carci-
noma in 167 carriers of RET germline mutations. Surgery
134(3):425–431
4. Machens A, Ukkat J, Brauckhoff M et al (2005) Advances in the
management of hereditary medullary thyroid cancer. J Intern Med
257(1):50–59
5. Wolfe HJ, Melvin KE, Cervi-Skinner SJ et al (1973) C-cell
hyperplasia preceding medullary thyroid carcinoma. N Engl J
Med 289(9):437–441
6. Donis-Keller H, Dou S, Chi D et al (1993) Mutations in the RET
proto-oncogene are associated with MEN 2A and FMTC. Hum
Mol Genet 2(7):851–856
7. Lips CJ, Landsvater RM, Hoppener JW et al (1994) Clinical
screening as compared with DNA analysis in families with
multiple endocrine neoplasia type 2A. N Engl J Med 331(13):
828–835
8. Mulligan LM, Kwok JB, Healey CS et al (1993) Germ-line
mutations of the RET proto-oncogene in multiple endocrine
neoplasia type 2A. Nature 363(6428):458–460
9. Machens A, Niccoli-Sire P, Hoegel J et al (2003) Early malignant
progression of hereditary medullary thyroid cancer. N Engl J Med
349(16):1517–1525
10. Skinner MA, Moley JA, Dilley WG et al (2005) Prophylactic
thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J
Med 353(11):1105–1113
11. Brandi ML, Gagel RF, Angeli A et al (2001) Guidelines for
diagnosis and therapy of MEN type 1 and type 2. J Clin Endo-
crinol Metab 86(12):5658–5671
12. de Groot JW, Links TP, Rouwe CW et al (2006) Prophylactic
thyroidectomy in children who are carriers of a multiple endo-
crine neoplasia type 2 mutation: description of 20 cases and
recommendations based on the literature. Ned Tijdschr Geneeskd
150(6):311–318
13. Gagel RF, Tashjian AH Jr, Cummings T et al (1988) The clinical
outcome of prospective screening for multiple endocrine neo-
plasia type 2a. An 18-year experience. N Engl J Med 318(8):
478–484
14. Orlandi F, Caraci P, Mussa A et al (2001) Treatment of medullary
thyroid carcinoma: an update. Endocr Relat Cancer 8(2):135–147
15. Machens A, Dralle H (2007) Genotype–phenotype based surgical
concept of hereditary medullary thyroid carcinoma. World J Surg
31(5):957–968
16. Dralle H, Gimm O, Simon D et al (1998) Prophylactic thyroid-
ectomy in 75 children and adolescents with hereditary medullary
thyroid carcinoma: German and Austrian experience. World J
Surg 22(7):744–750 (discussion 750–741)
17. Gill JR, Reyes-Mugica M, Iyengar S et al (1996) Early presen-
tation of metastatic medullary carcinoma in multiple endocrine
World J Surg (2010) 34:852–860 859
123
neoplasia, type IIA: implications for therapy. J Pediatr 129(3):
459–464
18. Samaan NA, Draznin MB, Halpin RE et al (1991) Multiple
endocrine syndrome type IIb in early childhood. Cancer 68(8):
1832–1834
19. Skinner MA, DeBenedetti MK, Moley JF et al (1996) Medullary
thyroid carcinoma in children with multiple endocrine neoplasia
types 2A and 2B. J Pediatr Surg 31(1):177–181 (discussion
181–172)
20. Stjernholm MR, Freudenbourg JC, Mooney HS et al (1980)
Medullary carcinoma of the thyroid before age 2 years. J Clin
Endocrinol Metab 51(2):252–253
21. Siggelkow H, Melzer A, Nolte W et al (2001) Presentation of a
kindred with familial medullary thyroid carcinoma and
Cys611Phe mutation of the RET proto-oncogene demonstrating
low grade malignancy. Eur J Endocrinol 144(5):467–473
22. Lindskog S, Nilsson O, Jansson S et al (2004) Phenotypic
expression of a family with multiple endocrine neoplasia type 2A
due to a RET mutation at codon 618. Br J Surg 91(6):713–718
23. Neocleous V, Passalaris T, Spanou E et al (2004) Description of
the first two seemingly unrelated Greek Cypriot families with a
common C618R RET proto-oncogene mutation. Genet Test
8(2):163–168
24. Frohnauer MK, Decker RA (2000) Update on the MEN 2A c804
RET mutation: is prophylactic thyroidectomy indicated? Surgery
128(6):1052–1057 (discussion 1057–1058)
860 World J Surg (2010) 34:852–860
123
